low - Clinical development timelines are independent of GDP cycles. However, capital markets conditions affect ability to raise financing for cash-intensive R&D. Biotech sector correlates with risk appetite rather than economic fundamentals. Healthcare spending on rare disease treatments is relatively recession-resistant.

Rising rates negatively impact valuation through higher discount rates applied to distant cash flows (products likely 2027+ launch). Pre-revenue biotechs are duration assets with negative near-term cash flows, making them highly sensitive to risk-free rate changes. Higher rates also increase cost of capital for future equity raises needed to fund development. Fed funds rate and 10-year Treasury yields directly affect biotech sector multiples.

growth - Attracts speculative biotech investors focused on binary clinical catalysts and platform technology potential. Recent 47% three-month return reflects momentum trading around clinical milestones. Not suitable for value or income investors given negative earnings and no dividend. Institutional ownership includes specialized healthcare funds and venture-style public market investors willing to accept 3-5 year development timelines.